HOUSTON, TX AND VANCOUVER, June 25, 2019 /PRNewswire/ - ESSA Pharma Inc. (`ESSA` or the `Company`) (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its annual general meeting of shareholders of the Company (the `Shareholders`) held on June 25, 2019 in Vancouver, British Columbia, Canada (the `Meeting`). At the Meeting, the Shareholders set the number of directors at seven and re-elected to the board of directors (the `Board`), by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Raymond Andersen, Gary...
|
